Author

Rajiv Mundayat

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Rajiv Mundayat  et al.

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Rajiv Mundayat  et al.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Rajiv Mundayat  et al.

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Rajiv Mundayat  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Rajiv Mundayat  et al.

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Rajiv Mundayat  et al.

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Rajiv Mundayat  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

Rajiv Mundayat  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Rajiv Mundayat  et al.

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Rajiv Mundayat  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Rajiv Mundayat  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

Rajiv Mundayat  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Rajiv Mundayat  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

Rajiv Mundayat  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Rajiv Mundayat  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Rajiv Mundayat  et al.

Item 1 - 16 / 16
1